{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:49:06Z","timestamp":1770227346356,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,20]]},"DOI":"10.7759\/cureus.90611","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T22:22:10Z","timestamp":1755728530000},"source":"Crossref","is-referenced-by-count":2,"title":["Atypical Femoral Fracture Secondary to Long-Term Bisphosphonate Use: A Case Report"],"prefix":"10.7759","author":[{"given":"Madhumati","family":"Mandal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqah","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Japheth","family":"Oyovwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliyu O","family":"Olaniyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Fayyaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1302\/2058-5241.3.170070","article-title":"The enigma of atypical femoral fractures: a summary of current knowledge","volume":"3","author":"Larsen MS","year":"2018","unstructured":"Larsen MS, Schmal H. The enigma of atypical femoral fractures: a summary of current knowledge. EFORT Open Rev. 2018, 3:494-500. 10.1302\/2058-5241.3.170070","journal-title":"EFORT Open Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane E","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, et al.. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014, 29:1-23. 10.1002\/jbmr.1998","journal-title":"J Bone Miner Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use","volume":"22","author":"Neviaser AS","year":"2008","unstructured":"Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008, 22:346-50. 10.1097\/BOT.0b013e318172841c","journal-title":"J Orthop Trauma"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115330","article-title":"Practical guidance for the use of bisphosphonates in osteoporosis","volume":"136","author":"Compston J","year":"2020","unstructured":"Compston J. Practical guidance for the use of bisphosphonates in osteoporosis. Bone. 2020, 136:115330. 10.1016\/j.bone.2020.115330","journal-title":"Bone"},{"key":"ref5","article-title":"Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis","volume":"11","author":"Nuti R","year":"2014","unstructured":"Nuti R. Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis. Clin Cases Miner Bone Metab. 2014, 11:208-14.","journal-title":"Clin Cases Miner Bone Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3211","article-title":"Bisphosphonates in the treatment of osteoporosis","volume":"344","author":"Poole KE","year":"2012","unstructured":"Poole KE, Compston JE. Bisphosphonates in the treatment of osteoporosis. BMJ. 2012, 344:e3211. 10.1136\/bmj.e3211","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black DM","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, et al.. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020, 383:743-53. 10.1056\/NEJMoa1916525","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2024.111346","article-title":"Prevalence of atypical femoral fractures, a clinical update: a comparative retrospective study 7 years later","volume":"55 Suppl 4","author":"Bottai V","year":"2024","unstructured":"Bottai V, Antognetti D, Troiano E, et al.. Prevalence of atypical femoral fractures, a clinical update: a comparative retrospective study 7 years later. Injury. 2024, 55 Suppl 4:111346. 10.1016\/j.injury.2024.111346","journal-title":"Injury"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jot.2016.06.029","article-title":"Atypical femoral fractures and current management","volume":"7","author":"Zheng N","year":"2016","unstructured":"Zheng N, Tang N, Qin L. Atypical femoral fractures and current management. J Orthop Translat. 2016, 7:7-22. 10.1016\/j.jot.2016.06.029","journal-title":"J Orthop Translat"},{"key":"ref10","unstructured":"National Osteoporosis Guideline Group. Clinical guideline for the prevention and treatment of osteoporosis. (2024). https:\/\/www.nogg.org.uk\/full-guideline\/NOGG-Guideline-2024.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma, version 2.2016: clinical practice guidelines in oncology","volume":"13","author":"Anderson KC","year":"2015","unstructured":"Anderson KC, Alsina M, Atanackovic D, et al.. Multiple myeloma, version 2.2016: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2015, 13:1398-435. 10.6004\/jnccn.2015.0167","journal-title":"J Natl Compr Canc Netw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.31599","article-title":"Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro","volume":"85","author":"Henneman ZJ","year":"2008","unstructured":"Henneman ZJ, Nancollas GH, Ebetino FH, Russell RG, Phipps RJ. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A. 2008, 85:993-1000. 10.1002\/jbm.a.31599","journal-title":"J Biomed Mater Res A"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer D","year":"2018","unstructured":"Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne). 2018, 9:788. 10.3389\/fendo.2018.00788","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003188.pub3","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","author":"Mhaskar R","year":"2012","unstructured":"Mhaskar R, Redzepovic J, Wheatley K, et al.. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012, CD003188. 10.1002\/14651858.CD003188.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3221","article-title":"Evaluating atypical features of femur fractures: how change in radiological criteria influenced incidence and demography of atypical femur fractures in a community setting","volume":"32","author":"LeBlanc ES","year":"2017","unstructured":"LeBlanc ES, Rosales AG, Black DM, et al.. Evaluating atypical features of femur fractures: how change in radiological criteria influenced incidence and demography of atypical femur fractures in a community setting. J Bone Miner Res. 2017, 32:2304-14. 10.1002\/jbmr.3221","journal-title":"J Bone Miner Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-009-0800-3","article-title":"Type of hip fracture determines load share in intramedullary osteosynthesis","volume":"467","author":"Eberle S","year":"2009","unstructured":"Eberle S, Gerber C, von Oldenburg G, Hungerer S, Augat P. Type of hip fracture determines load share in intramedullary osteosynthesis. Clin Orthop Relat Res. 2009, 467:1972-80. 10.1007\/s11999-009-0800-3","journal-title":"Clin Orthop Relat Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s43465-020-00291-4","article-title":"Research update on stress riser fractures","volume":"55","author":"Yoo J","year":"2021","unstructured":"Yoo J, Ma X, Lee J, Hwang J. Research update on stress riser fractures. Indian J Orthop. 2021, 55:560-70. 10.1007\/s43465-020-00291-4","journal-title":"Indian J Orthop"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3109\/17453674.2015.1036339","article-title":"Bisphosphonate-associated peri-implant fractures: a new clinical entity? A series of 10 patients with 11 fractures","volume":"86","author":"Lee JY","year":"2015","unstructured":"Lee JY, Soh T, Howe TS, Koh JS, Kwek EB, Chua DT. Bisphosphonate-associated peri-implant fractures: a new clinical entity? A series of 10 patients with 11 fractures. Acta Orthop. 2015, 86:622-6. 10.3109\/17453674.2015.1036339","journal-title":"Acta Orthop"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-D-16-00717","article-title":"Surgical management of atypical femur fractures associated with bisphosphonate therapy","volume":"26","author":"Githens M","year":"2018","unstructured":"Githens M, Garner MR, Firoozabadi R. Surgical management of atypical femur fractures associated with bisphosphonate therapy. J Am Acad Orthop Surg. 2018, 26:864-71. 10.5435\/JAAOS-D-16-00717","journal-title":"J Am Acad Orthop Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0986-y","article-title":"Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?","volume":"21","author":"Edwards MH","year":"2010","unstructured":"Edwards MH, McCrae FC, Young-Min SA. Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?. Osteoporos Int. 2010, 21:701-3. 10.1007\/s00198-009-0986-y","journal-title":"Osteoporos Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100259","article-title":"Atypical femoral fractures from bisphosphonate in cancer patients - review","volume":"18","author":"Lockwood M","year":"2019","unstructured":"Lockwood M, Banderudrappagari R, Suva LJ, Makhoul I. Atypical femoral fractures from bisphosphonate in cancer patients - review. J Bone Oncol. 2019, 18:100259. 10.1016\/j.jbo.2019.100259","journal-title":"J Bone Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/378460-atypical-femoral-fracture-secondary-to-long-term-bisphosphonate-use-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T22:22:12Z","timestamp":1755728532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/378460-atypical-femoral-fracture-secondary-to-long-term-bisphosphonate-use-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.90611","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}